Clinical trials: Antiplatelet Drug
Coronary Artery Disease, Percutaneous Coronary Intervention
Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration
this study is an individual patient level meta-analysis of randomized clinical trials, to evaluate the influence of ethnicity, to study whether the relative tradeoff between ischemia and bleeding is distinct by ethnicity.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03338335
- Testing
- prolonged DAPT
- Where
- South Korea
- Volunteers
- 16,000 people
- Sponsor
- Seoul National University Hospital
OGD, Gastric Ulcer Induced by Anti-platelet Agent
Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents
OBJECTIVES: Up to 15% of patients with peptic ulcer bleeding will develop rebleeding, mainly in those with ulcers of higher-risk stigmata (i.e. Forrest class Ia to IIb).
- Conditions
- OGD, Gastric Ulcer Induced by Anti-platelet Agent, Duodenal Ulcer Induced by Anti-platelet Agent
- Trial name
- NCT02840929
- Testing
- Second-look OGD, Esomeprazole
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 2 people
- Sponsor
- The University of Hong Kong
Vascular Disease, Coronary Artery Disease Risk Factors Multiple
Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors
This study is a Phase I, intravenous, single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PZ-128 (pepducin inhibitor of PAR1) in subjects with vascular disease or who have 2…
- Trial name
- NCT01806077
- Testing
- PZ-128
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Tufts Medical Center
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Coronary Artery Disease, Percutaneous Coronary Intervention
Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)
The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- RICH (NCT05746416)
- Where
- South Korea
- Volunteers
- 977 people
- Sponsor
- Hanyang University Seoul Hospital
Craniocerebral Trauma, Cerebral Hemorrhage
Mild Head Injury, Antiplatelets, and Anticoagulants
Approximately 20% of patients with mild head injury presenting to the Emergency Department (ED) is taking antiplatelet agents and 10% is taking oral anticoagulants.
- Trial name
- NCT04741334
- Testing
- direct anticoagulant, antiplatelet drugs, Dicumarols
- Where
- Italy
- Volunteers
- 2,127 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dental Diseases, Antiplatelet Agents
Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure.
This is a prospective randomized open-label blinded endpoint (PROBE) The study will be conducted in Maharaj Nakorn Chiang Mai hospital.
- Conditions
- Dental Diseases, Antiplatelet Agents, Antiplatelet Drugs
- Trial name
- NCT03103685
- Testing
- Clopidogrel
- Volunteers
- 428 people
- Sponsor
- Chiang Mai University
Acute Coronary Syndrome
Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
The target population of this interventional study was ACS patients with drug-coated balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet therapy compared with dual antiplatelet therapy alone…
- Trial name
- NCT05750758
- Testing
- rivaroxaban
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Coronary Artery Disease, Myocardial Infarction
Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis
The primary objective of this study is to establish a cut off level of platelet inhibition that separates patients with or without previous stent occlusion with acute clinical onset while on aspirin and clopidogrel treatment…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Stent Thrombosis, Heart Diseases
- Trial name
- TOPAS-1 (NCT00914368)
- Testing
- Clopidogrel
- Where
- Sweden
- Volunteers
- 450 people
- Sponsor
- Uppsala University
Coronary Artery Disease
IU Health Krannert Personalized Medicine Study
Randomized controlled study to examine physician use of pharmacogenetic information in patients receiving antiplatelet medication after percutaneous coronary intervention (PCI).
- Trial name
- NCT02955121
- Testing
- Prescriber Access to Genetic Information
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Indiana University
Obscure Gastrointestinal Bleeding, Iron-Deficiency Anemia
Endoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy
This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB).
- Conditions
- Obscure Gastrointestinal Bleeding, Iron-Deficiency Anemia, Antithrombotic Therapy
- Trial name
- BEACON-IDA (NCT07089030)
- Testing
- Standard endoscopic evaluation, Conservative Medical Management
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
Coronary Artery Bypass, Antiplatelet Agents
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1…
- Trial name
- DACAB (NCT02201771)
- Testing
- Aspirin, Ticagrelor
- Where
- 6 sites in China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Acute Coronary Syndromes, STEMI
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular…
- Conditions
- Acute Coronary Syndromes, STEMI, NSTEMI, Unstable Angina
- Trial name
- SAPT-ACS (NCT07684742)
- Testing
- Early P2Y12 Inhibitor Monotherapy, Standard Dual Antiplatelet Therapy
- Where
- South Korea
- Volunteers
- 1,900 people
- Sponsor
- Gyeongsang National University Hospital
Acute Coronary Syndrome
Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome
The study aims to determine the pharmacodynamic performance in the first hour measured with verifynow, of the conventional ticagrelor loaded dose versus chewed ticagrelor in patients with acute coronary syndrome treated with…
- Trial name
- TICA-MASTICA (NCT04567290)
- Testing
- Chewed ticagrelor, Swallowed ticagrelor
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Centro Hospitalario La Concepcion